| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-475 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52 |
| filingDate |
1996-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6464e8339140b873807e1c50f9f0a6d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_264de2fb7faf8ebb387935ffd52e6488
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f3ab1f897fb1603e44e146f925ed49d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b92bd3a119cd62b25c6473e389a85256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8a7ef9e6eb13cdebf7cd573ef6b5bfc |
| publicationDate |
1997-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0802795-A1 |
| titleOfInvention |
Neurological drug screens |
| abstract |
Compositions for identifying lead compounds for pharmacological agents useful in the diagnosis or treatment of neurological disease or injury include mixtures comprising an isolated netrin and an isolated natural netrin receptor such as 'Deleted in Colorectal Carcinoma' (DCC) and neogenin. The general methods involve incubating a mixture of an isolated mammalian netrin, an isolated natural mammalian netrin receptor, and a candidate pharmacological agent, and determining if the presence of the agent modulates the binding of the netrin to the receptor. |
| priorityDate |
1995-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |